Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


Mucosis receives financial support from the Dutch government for its Flugem program


Groningen, the Netherlands, May 31, 2010 - Dutch vaccine development company Mucosis B.V. announced today that it has received an innovation credit line of approximately € 3 million from Agentschap NL, an agency of the Dutch Ministry of Economic Affairs. Mucosis will use this loan towards the clinical development of its lead product FluGEM™, an influenza vaccine that can be administered by a simple spray in the nose. The loan will be redeemed only if the FluGEM™ clinical development program is concluded successfully.

“We are really pleased with the government’s financial support. This non-dilutive funding underlines the progress we have made so far and, even more importantly, strengthens our financial capabilities going forward. It will enable us to generate proof of efficacy with FluGEM™ in man” said Govert Schouten, CEO of Mucosis.

Mucosis develops novel vaccines on the basis of its unique Mimopath™ technology. This invention is key to the growth strategy for the coming years.

About Mucosis - www.mucosis.com
Mucosis B.V. is a Dutch biotechnology company developing innovative mucosal vaccines that can be applied needle-free via the nose or mouth. Mucosis’s lead product candidates are FluGEM™, an intranasal vaccine to prevent influenza, and PneuGEM™, a vaccine preventing diseases caused by pneumococcal bacteria. Mucosis’s vaccines are based on the patented Mimopath™ technology. This technology enables a more natural immune response as well as a broad base of protection.

About Mimopath™ technology - http://www.mucosis.com/mimopath.php
Mimopath™ technology is based on Lactococcus lactis, a safe bacterium commonly used in the food industry. Mucosis has developed an easy technique to formulate the L. lactis bacteria into non-living particles that can be loaded with antigens from viral, bacterial, or parasitic origin. The antigen-covered particles form a vaccine that can be delivered into the nose or mouth, without the need for a needle. These vaccines raise protective immunity by activation of both the innate and the adaptive immune system.

About Agentschap NL - http://www.agentschapnl.nl/
Agentschap NL is an agency of the Dutch Ministry of Economic Affairs. Its stimulation programs and different subsidy schemes target high technology, energy and climate, the environment, international businesses and collaboration. The innovation credit line (innovatiekrediet) is aimed at supporting innovative and commercially attractive development projects with an interest-bearing loan of which repayment is waived if the project fails.


For further information please contact:
Govert Schouten
CEO Mucosis
+31 (6) 55320948
govert.schouten@mucosis.com
www.mucosis.com
Meditech Center
L.J. Zielstraweg 1
9713 GX Groningen
The Netherlands


Publisher Contact Information:

Mucosis
+31 (6) 55320948
govert.schouten@mucosis.com

Company profile of Mucosis
Past press releases of Mucosis.

Data


19,194
Tech investments
From our Online Data Service
12,344
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Dec 16N/AMedical devices
Dec 15€6.0MBiopharmaceuticals
Dec 15€13.9MConsumer applications
Dec 15€4.0MBusiness applications
Dec 11N/AE-Commerce
Dec 8€13.7MOther Computers & Electronics
Dec 8€2.4MBroadcast

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


Dec 22
MobiForms
mobile charting support added to revolutionary mobiforms developer ...

Dec 11
Versatile Security
versatile security releases vsec:cms k2.0

Nov 26
IP Group
ip group - portfolio company and university of oxford spin-out geno...

Nov 25
High-Tech Gründerfonds Management
bioprocess technology company ps biotech gmbh receives series a fun...

Nov 25
Promethera Biosciences
promethera biosciences raises €25.33 million ($31.4 million) in ser...





About usContact usLegal Information
Copyright © 1999-2014
Emerging Technology Research Europe Inc. All rights reserved.